“…Amphotericin B is a second‐line drug administered by slow intravenous infusion in intractable cases and resistant mucosal disease. The requirement for parenteral administration, frequent monitoring, prolonged treatment, and dangerous side‐effects of the above agents have prompted the search for more convenient and less costly treatment modalities, as shown in Table 2 1,2,6–8 …”